Forecast to Publish a Notice of Funding Opportunity for Paul Calabresi Career Development Award in Clinical Oncology (K12 Clinical Trial Optional)
National Institutes of Health
Classification and identifiers
- Solicitation number
- NOT-CA-25-105
- Assistance listing (CFDA)
- 93.398
Amount
Amount not published by the funder
Who can apply
About this opportunity
The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO), the Paul Calabresi Career Development Award for Clinical Oncology (K12). The NOFO will invite applications for institutional research career development programs to support the training of clinical scientists in cancer research. The purpose of the Paul Calabresi Career Development Award for Clinical Oncology, is to increase the number of clinician-scientists trained in clinical and translational cancer research, promote their career development, and prepare them to be effective scientific partners with basic research scientists. NCI Calabresi K12 programs are required to have at least two oncology specialties represented among the included faculty and the pool of K12 appointees (Scholars). The pr...
Related opportunities
- Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)National Institutes of HealthCloses Mar 2029
- Forecast to Publish a Notice of Funding Opportunity for Academic Career Excellence (ACE) Award (K32 - Clinical Trial Required)National Institutes of Health
- Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)National Institutes of Health
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)National Institutes of HealthCloses Oct 2027Up to $300K
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)National Institutes of HealthCloses Oct 2026Up to $600K
- Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)National Institutes of Health